Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
Current Oncology · 30.08.2023 · 30 (9) · 8005-8018
DOI: 10.3390/curroncol30090581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 30.08.2023. Verfasst von John Paul Yun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Decitabine, Uridine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiho Pharma Canada, Inc..
Abstract (Originalsprache)
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C through a Canadian compassionate use program. Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada’s Patient Support Program were collected and analyzed. These patients represent a collection period from 10 November 2020 to 31 August 2022 with a median age of 76 years. Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles. The median overall and progression-free survival were 21.6 and 10.7 months, respectively. Among 427 patients who discontinued treatment, the majority (69.5%) stopped due to death (n = 164) or disease progression (n = 133). Multivariable cox regression showed that age, province of residence, blast counts, antibiotic prophylaxis, and number of dose reductions and delays were not significantly associated with overall and progression-free survival. DEC-C is a promising alternative to parenteral hypomethylating agent therapy, and it likely addresses an important unmet need for effective and convenient therapies in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.
- Galway University Hospital, H91 YR71 Galway, Ireland.
- Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Taiho Pharma Canada, Inc., Oakville, ON L6H 5R7, Canada.
- Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
ORCID-Profile: Philip Q Ding
Förderung
- Taiho Pharma Canada, Inc.
Zitieren
APA
Yun, J. P., Ding, P. Q., Dolley, A., & Cheung, W. Y. (2023). Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada. Current Oncology, 30(9), 8005-8018. https://doi.org/10.3390/curroncol30090581
Vancouver
Yun JP, Ding PQ, Dolley A, Cheung WY. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada. Current Oncology. 2023;30(9):8005-8018. doi:10.3390/curroncol30090581
BibTeX
@article{Yun2023,
author = {Yun, John Paul and Ding, Philip Q and Dolley, Aastha and Cheung, Winson Y},
title = {Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {9},
pages = {8005--8018},
doi = {10.3390/curroncol30090581}
}
EUVIMED